Clinical Trial Update: A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093 [Phase 1]

View source ↗

Summary

Phase I trial evaluating safety, tolerability, pharmacokinetics, and EEG effects of single rising oral doses of BIA 2-093 in epilepsy; study completed and resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• BIA 2-093

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Epilepsy | Phase 1 | Status: COMPLETED | Results posted: 2015-01-07